Board of Directors
Alan E. Walts, PhD
Alan Walts, PhD, is a founding board member and currently serves as Executive Chairman of PIC Therapeutics. Alan also serves as Executive Chairman of Artax Biopharma, Chairman of Aura Biosciences, is a co-founder and Board Observer of Arrakis Therapeutics, a board observer at Amylyx Pharmaceuticals, and is a Director of the Termeer Foundation. Dr. Walts is a US-based Venture Partner with Advent Life Sciences and is an Advisory Board member of the ALS Investment Fund. He has over 25 years of industry experience at Genzyme in business development, business strategy, R&D, general management, and venture capital. Prior to leaving Genzyme in 2013, Dr. Walts most recently managed Genzyme’s corporate venture fund, Genzyme Ventures (now Sanofi Ventures). He received a PhD in chemistry from MIT in 1985, carried out post-doctoral research in biochemistry at MIT with Professor Christopher Walsh, and completed the executive Program for Management Development at Harvard Business School.
Dr. Kathy Bowdish
President & CEO
Dr. Bowdish joined PIC Therapeutics as its President & CEO in August 2020, bringing more than 20 years of biopharmaceutical business and scientific leadership to the company.
Kathy was most recently at Sanofi, where she launched and led Sanofi Sunrise, a venture investment and partnering vehicle to accelerate early stage pioneering science for patients benefit, and more recently served as Vice President and Head of R&D Strategy.
Prior to her leadership roles at Sanofi, Kathy co-founded or led several early-stage life science companies focused on biological therapies. Kathy’s positions include President & CSO, Permeon Biologics; President & CEO, Anaphore; President, Alexion Antibody Technologies and Senior Vice President, Alexion Pharmaceuticals and Founder, CEO & CSO, Prolifaron, prior to its acquisition by Alexion.
Kathy has served on the Boards of Directors of MyoKardia, Warp Drive Bio, Portal Instruments, Thermalin, Permeon Biologics, Anaphore and Prolifaron, and most recently as an Observer on the DiCE Molecules Board. Kathy received her Ph.D. in molecular genetics from Columbia University College of Physicians and Surgeons, and her B.Sc. degree in biology from the College of William and Mary.
Richard Peters, MD, PhD
Dr. Peters is a co-founder of PIC Therapeutics. With over 25 years of experience in industry and academia, he is an active founder and angel biotech investor. He is currently President & CEO of Yumanity Therapeutics (NASDAQ:YMTX). He is also a co-founder of X4 Pharmaceuticals (NASDAQ:XFOR), Director and Chair of the Organization & Compensation Committee for Aprea Therapeutics (NASDAQ:APRE), investor and corporate advisor to Aura Biosciences. Previously, Dr. Peters served as President, CEO, and Director of Merrimack Pharmaceuticals (NASDAQ:MACK). He also held several roles at Sanofi (NASDAQ:SNY): Senior Vice President and Head of Global Rare Diseases, Head of Japan and Asia Pacific for Specialty, Oncology Division Medical Officer, and Head of Global and US Medical Affairs at Genzyme Transplant/Oncology. He has also served as a Senior Director at Onyx Pharmaceuticals, as a Director at Amgen (NASDAQ:AMGN), and as Chief Executive Officer of Mednav, a venture capital-backed healthcare information technology start-up. Dr. Peters is a Harvard-trained physician-scientist and has served on the faculty at the Massachusetts General Hospital and completed a Howard Hughes Medical Institute Fellowship in biophysics at Harvard Medical School.
Ms. Termeer leads the Termeer family office and holds a variety of directorship and governance roles at several of the Boston area's leading academic, charitable, and medical institutions. She is a member of the Board of Fellows and the Discovery Committee at Harvard Medical School and of the President's Council at Massachusetts General Hospital. In 2011, together with her late husband, Henri Termeer, she established the Henri and Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital with the goal of developing a best in class center for personalized medicine, building on Mr. Termeer's work as Genzyme's CEO focused on rare diseases. In addition, Ms. Termeer is a member of the Women in Science and Engineering Committee at the Museum of Science and is a Trustee Emerita of the Boston Ballet.
Gerhard Wagner, PhD
Scientific Co-Founder, Director
Dr. Wagner is the Scientific Co-Founder of PIC Therapeutics and is world-renowned as a leading expert in NMR spectroscopy. During his tenure at the University of Michigan in Ann Arbor, he developed triple-resonance methods and the procedures for studies of protein dynamics. Since 1990, Dr. Wagner has been a Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. His research focuses on eukaryotic translation initiation, transcriptional activation and membrane proteins in micelles and nanodiscs. A particular focus of his research is on discovery and characterization of small molecule inhibitors of protein-protein interactions. He has been elected to the German National Academy of Sciences (Leopoldina), The National Academy of Science USA and the American Academy of Arts and Sciences. Dr. Wagner obtained his PhD from the ETH Zürich in 1977 with NMR studies of protein dynamics.